Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply

Samankaltaisia teoksia

• Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study
  Tekijä: Nakaoka, Yoshikazu, et al.
  Julkaistu: (2020)
• Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)
  Tekijä: Nakaoka, Yoshikazu, et al.
  Julkaistu: (2018)
• Perioperative Management of Takayasu Arteritis for Cardiac Surgery in a Patient Treated With Tocilizumab
  Tekijä: Arita, Yoh, et al.
  Julkaistu: (2020)
• Was it a case of Takayasu arteritis?
  Tekijä: Smith, M, et al.
  Julkaistu: (2002)
• Subcutaneous administration of tocilizumab is effective in myointimal hyperplasia remodelling in refractory Takayasu arteritis
  Tekijä: A. Lo Gullo, et al.
  Julkaistu: (2017-12-01)